Objectives
The effect of moxifloxacin on QT interval is reversible and dose-related; mainly provided by weakly but rapidly activated rectifying potassium channel blockade, IKr or HERG (human ether-a-go-go-related gene) potassium channels. Retrospective data suggest an increase in cardiac event rates with moxifloxacin use. Nevertheless, except for case reports and experimental trials about QT/QTc, there is insufficient data in the literature on the incidence of cardiac arrhythmias detected by ECG and Holter monitoring.
Methods
In this trial, we sought to determine the effects of newly administrated oral moxifloxacin (with the indications of upper airway infections, community-acquired pneumonia and acute exaggerated bronchitis) on the incidence of cardiac arrhythmias. All patients were screened for cardiac arrhythmia before therapy (0th day – BT), on the 3th day (during therapy – DT) and on the 10th day (after therapy – AT) with ECG and on the 3th day and on the 10th day with Holter monitorization. Before starting of the therapy, structural heart diseases were excluded using echocardiography, other exclusion criteria were based on the laboratory tests.
Methods
In this trial, we sought to determine the effects of newly administrated oral moxifloxacin (with the indications of upper airway infections, community-acquired pneumonia and acute exaggerated bronchitis) on the incidence of cardiac arrhythmias. All patients were screened for cardiac arrhythmia before therapy (0th day – BT), on the 3th day (during therapy – DT) and on the 10th day (after therapy – AT) with ECG and on the 3th day and on the 10th day with Holter monitorization. Before starting of the therapy, structural heart diseases were excluded using echocardiography, other exclusion criteria were based on the laboratory tests.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
